.Pharmacolibrary.Drugs.L_AntineoplasticAndImmunomodulatingAgents.L01B_Antimetabolites.L01BC05_Gemcitabine.Gemcitabine .Pharmacolibrary.Drugs.L_AntineoplasticAndImmunomodulatingAgents.L01B_Antimetabolites.L01BC05_Gemcitabine.Gemcitabine| name: | Gemcitabine |
| ATC code: | L01BC05 | route: | intravenous |
| n-compartments | 2 |
Gemcitabine is a nucleoside analog used as an antineoplastic (anticancer) agent. It is approved and widely used for treatment of various carcinomas, including pancreatic cancer, non-small cell lung cancer, bladder cancer, and breast cancer. It works primarily by inhibiting DNA synthesis, leading to cell death.
Pharmacokinetic parameters reported for adult cancer patients (both sexes), typically aged 18-80 years, receiving intravenous infusion of gemcitabine. No major differences were observed based on sex or cancer type.
Sugiyama, E, et al., & Sawada, J (2010). Population pharmacokinetics of gemcitabine and its metabolite in Japanese cancer patients: impact of genetic polymorphisms. Clinical pharmacokinetics 49(8) 549–558. DOI:10.2165/11532970-000000000-00000 PUBMED:https://pubmed.ncbi.nlm.nih.gov/20608756
Boosman, RJ, et al., & Huitema, ADR (2022). Is age just a number? A population pharmacokinetic study of gemcitabine. Cancer chemotherapy and pharmacology 89(5) 697–705. DOI:10.1007/s00280-022-04431-5 PUBMED:https://pubmed.ncbi.nlm.nih.gov/35426526
Jiang, X, et al., & McLachlan, AJ (2008). Population pharmacokinetics of gemcitabine and its metabolite in patients with cancer: effect of oxaliplatin and infusion rate. British journal of clinical pharmacology 65(3) 326–333. DOI:10.1111/j.1365-2125.2007.03040.x PUBMED:https://pubmed.ncbi.nlm.nih.gov/17961191